Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Blood

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Blood|February 18, 2009
Interleukin-33: a regulator of basophilsPeter Valent
Blood|August 30, 2014
Targeting the JAK2-STAT5 pathway in CMLPeter Valent
Blood|November 17, 2017
Anemia at older age: etiologies, clinical implications, and managementReinhard Stauder, Peter Valent, Igor Theurl
Blood|September 22, 2010
How I treat patients with advanced systemic mastocytosisPeter Valent, Wolfgang R Sperr, Cem Akin
Blood|December 30, 2016
Mastocytosis: 2016 updated WHO classification and novel emerging treatment conceptsPeter Valent, Cem Akin, Dean D Metcalfe
Blood|October 24, 2002
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycinMatthias Mayerhofer, Peter Valent, Wolfgang R Sperr, et al.
Blood|December 20, 2014
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitorsPeter Valent, Emir Hadzijusufovic, Gerit-Holger Schernthaner, et al.
Blood|June 5, 2002
Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosisBernhard Angermayr, Manfred Cejna, Maria Schoder, et al.
Blood|November 18, 2006
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412Karl J Aichberger, Matthias Mayerhofer, Karoline V Gleixner, et al.
Blood|August 28, 2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsUwe Rix, Oliver Hantschel, Gerhard Dürnberger, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Blood|February 18, 2009
Interleukin-33: a regulator of basophilsPeter Valent
Blood|August 30, 2014
Targeting the JAK2-STAT5 pathway in CMLPeter Valent
Blood|November 17, 2017
Anemia at older age: etiologies, clinical implications, and managementReinhard Stauder, Peter Valent, Igor Theurl
Blood|September 22, 2010
How I treat patients with advanced systemic mastocytosisPeter Valent, Wolfgang R Sperr, Cem Akin
Blood|December 30, 2016
Mastocytosis: 2016 updated WHO classification and novel emerging treatment conceptsPeter Valent, Cem Akin, Dean D Metcalfe
Blood|October 24, 2002
BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycinMatthias Mayerhofer, Peter Valent, Wolfgang R Sperr, et al.
Blood|December 20, 2014
Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitorsPeter Valent, Emir Hadzijusufovic, Gerit-Holger Schernthaner, et al.
Blood|June 5, 2002
Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosisBernhard Angermayr, Manfred Cejna, Maria Schoder, et al.
Blood|November 18, 2006
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412Karl J Aichberger, Matthias Mayerhofer, Karoline V Gleixner, et al.
Blood|August 28, 2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targetsUwe Rix, Oliver Hantschel, Gerhard Dürnberger, et al.
Pageof 6